156 related articles for article (PubMed ID: 37895919)
1. Oxaliplatin Enhances the Apoptotic Effect of Mesenchymal Stem Cells, Delivering Soluble TRAIL in Chemoresistant Colorectal Cancer.
Quiroz-Reyes AG; Delgado-González P; Islas JF; Soto-Domínguez A; González-Villarreal CA; Padilla-Rivas GR; Garza-Treviño EN
Pharmaceuticals (Basel); 2023 Oct; 16(10):. PubMed ID: 37895919
[TBL] [Abstract][Full Text] [Related]
2. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
[TBL] [Abstract][Full Text] [Related]
3. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
4. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects.
Yu R; Deedigan L; Albarenque SM; Mohr A; Zwacka RM
Cell Death Dis; 2013 Feb; 4(2):e503. PubMed ID: 23429289
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
6. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence.
Luetzkendorf J; Mueller LP; Mueller T; Caysa H; Nerger K; Schmoll HJ
J Cell Mol Med; 2010 Sep; 14(9):2292-304. PubMed ID: 19508388
[TBL] [Abstract][Full Text] [Related]
8. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pejenaute-Ochoa D; Jarauta V; Marzo I; Fernández LJ; Ochoa I; Conde B; Anel A; Martinez-Lostao L
Cancer Lett; 2016 Dec; 383(2):250-260. PubMed ID: 27725224
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
10. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
[TBL] [Abstract][Full Text] [Related]
11. Human Umbilical Cord MSC Delivered-Soluble TRAIL Inhibits the Proliferation and Promotes Apoptosis of B-ALL Cell In Vitro and In Vivo.
Chen F; Zhong X; Dai Q; Li K; Zhang W; Wang J; Zhao Y; Shen J; Xiao Z; Xing H; Li J
Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36422522
[TBL] [Abstract][Full Text] [Related]
12. Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells.
De Miguel D; Gallego-Lleyda A; Ayuso JM; Pawlak A; Conde B; Ochoa I; Fernández LJ; Anel A; Martinez-Lostao L
Recent Pat Anticancer Drug Discov; 2016; 11(2):197-214. PubMed ID: 26924736
[TBL] [Abstract][Full Text] [Related]
13. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
14. Chemo-Sensitization of CD133+ Cancer Stem Cell Enhances the Effect of Mesenchymal Stem Cell Expressing TRAIL in Non-Small Cell Lung Cancer Cell Lines.
Fakiruddin KS; Lim MN; Nordin N; Rosli R; Abdullah S
Biology (Basel); 2021 Oct; 10(11):. PubMed ID: 34827096
[TBL] [Abstract][Full Text] [Related]
15. A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement.
Quiroz-Reyes AG; González-Villarreal CA; Martínez-Rodriguez H; Said-Fernández S; Salinas-Carmona MC; Limón-Flores AY; Soto-Domínguez A; Padilla-Rivas G; Montes De Oca-Luna R; Islas JF; Garza-Treviño EN
Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35485288
[TBL] [Abstract][Full Text] [Related]
16. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
17. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
19. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.
Ziauddin MF; Guo ZS; O'Malley ME; Austin F; Popovic PJ; Kavanagh MA; Li J; Sathaiah M; Thirunavukarasu P; Fang B; Lee YJ; Bartlett DL
Gene Ther; 2010 Apr; 17(4):550-9. PubMed ID: 20182517
[TBL] [Abstract][Full Text] [Related]
20. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade.
Huang KC; Chiang SF; Chang HY; Chen WT; Yang PC; Chen TW; Liang JA; Shiau AC; Ke TW; Clifford Chao KS
Cell Death Dis; 2022 Jul; 13(7):610. PubMed ID: 35835756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
